{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T22:06:58Z","timestamp":1748470018817,"version":"3.41.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The aim of this study was to evaluate treatment patterns and overall survival (OS) of patients with BRAF<jats:sup>V600<\/jats:sup> wild-type and BRAF<jats:sup>V600<\/jats:sup>-mutant advanced melanoma in the Netherlands.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We selected patients of 18 years and over, diagnosed between 2016 and 2017 with unresectable stage IIIC or IV melanoma, registered in the Dutch Melanoma Treatment Registry. To assess the association of BRAF<jats:sup>V600<\/jats:sup>-mutation status with OS we used the Cox proportional-hazards model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 642 BRAF<jats:sup>V600<\/jats:sup> wild-type and 853 mutant patients were included in the analysis. Median OS did not differ significantly between both groups, 15.2 months (95% confidence interval [CI]: 13.2-19.2) versus 20.6 months (95% CI: 18.3-25.0). Survival rates at 6 and 12 months were significantly lower for BRAF<jats:sup>V600<\/jats:sup> wild-type patients compared with BRAF<jats:sup>V600<\/jats:sup>-mutant patients, 72.0% (95% CI: 68.6-75.6) and 56.0% (95% CI: 52.2-60.0) versus 83.4% (95% CI: 80.9-85.9) and 65.7% (95% CI: 62.6-69.0). Two-year survival was not significantly different between both groups, 41.1% (95% CI: 37.2-45.3) versus 47.0% (95% CI: 43.6-60.6). Between 0 and 10 months, BRAF<jats:sup>V600<\/jats:sup> wild-type patients had a decreased survival with a hazard ratio for OS of 2.00 (95% CI: 1.62-2.46) but this effect disappeared after 10 months. At 12 months, BRAF<jats:sup>V600<\/jats:sup>-mutant patients had started with second-line systemic treatment more often compared with BRAF<jats:sup>V600<\/jats:sup> wild-type patients (50% vs. 19%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>These results suggest that advanced BRAF<jats:sup>V600<\/jats:sup> wild-type melanoma patients have worse survival than BRAF<jats:sup>V600<\/jats:sup>-mutated patients during the first 10 months after diagnosis because of less available treatment options.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000786","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T22:32:44Z","timestamp":1608244364000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status"],"prefix":"10.1097","volume":"44","author":[{"given":"Jesper","family":"van Breeschoten","sequence":"first","affiliation":[{"name":"Dutch Institute for Clinical Auditing"},{"name":"Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel W.J.M","family":"Wouters","sequence":"additional","affiliation":[{"name":"Dutch Institute for Clinical Auditing"},{"name":"Surgical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth C.","family":"de Wreede","sequence":"additional","affiliation":[{"name":"Biomedical Data Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doranne H.","family":"Hilarius","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Rode Kruis Ziekenhuis, Beverwijk"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Haanen","sequence":"additional","affiliation":[{"name":"Medical Oncology and Immunology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[{"name":"Medical Oncology and Immunology"},{"name":"Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen J.B","family":"Aarts","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Maastricht University Medical Centre, Maastricht"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franchette W.P.J.","family":"van den Berkmortel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zuyderland Medical Centre Sittard, Sittard-Geleen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Willem B.","family":"de Groot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Isala Oncological Center, Zwolle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geke A.P.","family":"Hospers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Centre Groningen, Groningen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[{"name":"Medical Oncology, Leiden University Medical Centre, Leiden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djura","family":"Piersma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medisch Spectrum Twente, Enschede"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rozemarijn S.","family":"van Rijn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karijn P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willeke A.M.","family":"Blokx","sequence":"additional","affiliation":[{"name":"Pathology, University Medical Centre Utrecht, Utrecht"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"ten Tije","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amphia Hospital, Breda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[{"name":"Medical Oncology"},{"name":"Radiology & Nuclear Medicine, Erasmus Medical Centre, Rotterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Vreugdenhil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maxima Medical Centre, Eindhoven"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marye J.","family":"Boers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfons J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study Global Burden","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjd.12346","article-title":"Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991","volume":"169","author":"Holterhues","year":"2013","journal-title":"Br J Dermatol"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2018.12.002","article-title":"The real-world impact of modern treatments on the survival of patients with metastatic melanoma","volume":"108","author":"Donia","year":"2019","journal-title":"Eur J Cancer"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/EDBK_174934","article-title":"Systemic therapy options for patients with unresectable melanoma","volume":"37","author":"Yushak","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"Heppt","year":"2017","journal-title":"BMC Cancer"},{"key":"R12-20250527","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","author":"Larkin","year":"2019","journal-title":"N Engl J Med [Internet]"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000786","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:03Z","timestamp":1748365683000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000786","relation":{},"ISSN":["0277-3732"],"issn-type":[{"type":"print","value":"0277-3732"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}